Management of Diabetic Neuropathy with Lateral Hallux Callus

Immediate Assessment and Risk Stratification

Examine the foot with shoes and socks removed to identify pre‑ulcerative lesions and signs of infection in patients with diabetic neuropathy. 1

Perform professional scalpel debridement of the lateral hallux callus by a foot‑care specialist to prevent ulceration in neuropathic patients. 2, 3
Recognize that callus formation under high‑pressure areas is a pre‑ulcerative lesion that strongly predicts future foot ulceration and therefore requires treatment. 2
Prescribe toe‑silicone or semi‑rigid orthotic devices to reduce excess callus on the toe in patients with pressure‑related callus formation. 2
When foot deformity markedly increases pressure, provide extra‑depth shoes, custom‑made footwear, or custom insoles to off‑load the area. 2

Restart gabapentin with patient education on titration; gabapentin provides effective pain relief for diabetic peripheral neuropathy and improves sleep, mood, and quality of life. 4, 5
Consider pregabalin (e.g., 100 mg three times daily) as an alternative first‑line agent; it has a more favorable adverse‑event profile compared with gabapentin. 1, 5
Duloxetine (60–120 mg daily) is an effective SNRI for diabetic neuropathic pain and also enhances quality of life. 1, 6, 5
Amitriptyline (10–75 mg at bedtime) may be used when contraindications are absent (e.g., no glaucoma, orthostatic hypotension, cardiovascular disease, or fall risk). 1, 6, 4
Avoid tricyclic antidepressants in patients with glaucoma, orthostatic hypotension, cardiovascular disease, or high fall risk. 6
Do not prescribe duloxetine to patients with hepatic disease. 6
Use gabapentin or pregabalin cautiously in patients who have edema. 6

Provide structured foot‑care education immediately; patients with neuropathy and a pre‑ulcerative callus are classified as IWGDF risk level 2–3 and require intensive education. 2
Arrange follow‑up visits every 1–3 months for high‑risk patients (neuropathy with pre‑ulcerative lesions). 2

Implement aggressive glycemic control to slow the progression of diabetic neuropathy, acknowledging that it does not reverse existing neuronal loss. 4
Review and intensify diabetes therapy when HbA1c is above target to further protect nerve health. 1, 6

The American Diabetes Association recommends considering Charcot foot when a diabetic patient with neuropathy presents with increased temperature, edema, and/or redness of the foot compared to the contralateral side, and using infrared thermometry to measure bilateral skin temperatures—a temperature difference >2°C suggests active Charcot 7
The International Diabetes Federation suggests confirming infection clinically by documenting at least 2 signs of inflammation: erythema, warmth, swelling, tenderness, pain, or purulent discharge, and measuring the extent of erythema—if >2 cm around any wound, this indicates moderate infection requiring broad-spectrum antibiotics 8, 9

The American College of Physicians recommends testing for loss of protective sensation using a 10-g Semmes-Weinstein monofilament at multiple sites on each foot, and performing at least one additional test: 128-Hz tuning fork for vibration, pinprick sensation, or ankle reflexes 10, 11
The American Heart Association suggests palpating dorsalis pedis and posterior tibial pulses bilaterally, and asking specifically about claudication, leg fatigue, or decreased walking speed 10, 11

The American Diabetes Association recommends inspecting feet daily including between all toes, using a mirror or caregiver assistance if needed, and washing feet daily with lukewarm water (<37°C), drying carefully especially between toes 11, 10
The International Diabetes Federation suggests applying emollients to dry skin but NOT between toes to prevent maceration, and never walking barefoot, in socks only, or in thin-soled slippers—even indoors 11, 10

The American College of Foot and Ankle Surgeons recommends prescribing properly fitting therapeutic footwear with adequate depth and cushioning, and considering custom-molded shoes or extra-depth shoes for patients with foot deformities 11, 10

The American Diabetes Association suggests that high-risk patients (history of ulcer/amputation, loss of protective sensation, peripheral artery disease, or foot deformity) require follow-up every 1-3 months, and moderate-risk patients (neuropathy or PAD alone) need evaluation every 3-6 months 11, 8
The International Diabetes Federation recommends that all diabetic patients require comprehensive annual foot examination at minimum 10, 11